Form 8-K - Current report:
SEC Accession No. 0001213900-24-090831
Filing Date
2024-10-25
Accepted
2024-10-25 16:43:23
Documents
14
Period of Report
2024-10-24
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0218621-8k_cerothe.htm   iXBRL 8-K 30719
  Complete submission text file 0001213900-24-090831.txt   250985

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE cero-20241024.xsd EX-101.SCH 3798
3 XBRL DEFINITION FILE cero-20241024_def.xml EX-101.DEF 26673
4 XBRL LABEL FILE cero-20241024_lab.xml EX-101.LAB 36817
5 XBRL PRESENTATION FILE cero-20241024_pre.xml EX-101.PRE 25297
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0218621-8k_cerothe_htm.xml XML 5944
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 241397546
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)